Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Autism Spectrum Disorder Market Report Overview
The Autism Spectrum Disorder (ASD) market size was $985.5 million in 2021 and is expected to achieve a CAGR of more than 15% during 2021-2031. ASD, also known as autism, is a highly heterogeneous disorder characterized by varying social and communication impairments and pervasive repetitive behaviors, in addition to a wide range of associated non-core symptoms. The ASD market is chronically underserved, with no approved treatments for the core symptoms or most of the associated non-core symptoms.
The Autism Spectrum Disorder market research report provides an overview of ASD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
To gain more information on the Autism Spectrum Disorder market forecast, download a free report sample
Market Size (2021) | $985.5 million |
CAGR (2021 – 2031) | >15% |
Forecast period | 2022-2031 |
Key Class of Drugs | Atypical Antipsychotics, SSRIs, other off-label therapies, and Cannabinoids |
Leading Players | AbbVie, Acadia Pharmaceuticals, Axial Therapeutics, Bristol Myers Squibb, Confluence Pharmaceuticals, Cox Biosciences, Curemark, Finch Therapeutics, Gedeon Richter, and Jazz Pharmaceuticals |
Autism Spectrum Disorder Market Drivers
10 new pipeline products with significantly higher costs of therapy when compared to the cost of the generic therapies will launch throughout the 7MM during the forecast period. Moreover, the potential for novel pharmacological therapies specifically indicated for the core symptoms of ASD, that is a major unmet need in the ASD market, could provide new options for patients.
Autism Spectrum Disorder Market Segmentation by Class of Drugs
The key classes of drugs in the autism spectrum disorder market are Atypical Antipsychotics, SSRIs, other off-label therapies, and Cannabinoids, among others. In 2021, Atypical Antipsychotics were the top-selling class of drugs.
Autism Spectrum Disorder Market Analysis, by Class of Drugs, 2021 (%)
For more ASD classes of drugs insights, download a free report sample
Autism Spectrum Disorder Market - Competitive Landscape
Some of the leading players in the autism spectrum disorder market are AbbVie, Acadia Pharmaceuticals, Axial Therapeutics, Bristol Myers Squibb, Confluence Pharmaceuticals, Cox Biosciences, Curemark, Finch Therapeutics, Gedeon Richter, and Jazz Pharmaceuticals.
Segments Covered in this Report
Autism Spectrum Disorder Market Class of Drugs Outlook (Value, $ Million, 2021-2031)
- Atypical Antipsychotics
- SSRIs
- Other off-label therapies
- Cannabinoids
Scope
This report provides
- Overview of ASD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized ASD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (children, adolescents, and adults) forecast from 2021 to 2031.
- Strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the ASD therapeutics market.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for ASD therapy. The most promising candidates in Phase III and IIb development are profiled.
- Analysis of the current and future market competition in the global ASD therapeutics market and insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ASD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ASD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Acadia Pharmaceuticals
Axial Therapeutics
Bristol Myers Squibb
Confluence Pharmaceuticals
Cox Biosciences
Curemark
Finch Therapeutics
Gedeon Richter
Jazz Pharmaceuticals
Johnson & Johnson
Otsuka
Paxmedica
Roche
Scioto Biosciences
Sumitomo Pharmaceuticals
Vanda Pharmaceuticals
Yamo Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What was the autism spectrum disorder market size in 2021?
The autism spectrum disorder market size was valued at $985.5 million in 2021.
-
What is the autism spectrum disorder market growth rate?
The autism spectrum disorder market is expected to achieve a CAGR of more than 15% during 2021-2031.
-
What are the key classes of drugs in the autism spectrum disorder market?
The key classes of drugs in the autism spectrum disorder market are Atypical Antipsychotics, SSRIs, other off-label therapies, and Cannabinoids.
-
Who are the leading players in the autism spectrum disorder market?
Some of the leading players in the autism spectrum disorder market are AbbVie, Acadia Pharmaceuticals, Axial Therapeutics, Bristol Myers Squibb, Confluence Pharmaceuticals, Cox Biosciences, Curemark, Finch Therapeutics, Gedeon Richter, and Jazz Pharmaceuticals.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.